These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 21585650)
1. Induction of tolerance to factor VIII by transient co-administration with rapamycin. Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650 [TBL] [Abstract][Full Text] [Related]
2. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII. Liu CL; Ye P; Lin J; Djukovic D; Miao CH J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505 [TBL] [Abstract][Full Text] [Related]
3. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin. Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758 [TBL] [Abstract][Full Text] [Related]
4. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin. Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM Front Immunol; 2020; 11():1293. PubMed ID: 32670285 [TBL] [Abstract][Full Text] [Related]
6. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated. Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202 [TBL] [Abstract][Full Text] [Related]
7. Tilt balance towards regulation: evolving new strategy for treatment of hemophilia inhibitors. Miao CH J Thromb Haemost; 2011 Aug; 9(8):1521-3. PubMed ID: 21649848 [No Abstract] [Full Text] [Related]
8. Adjuvant facilitates tolerance induction to factor VIII in hemophilic mice through a Foxp3-independent mechanism that relies on IL-10. Oliveira VG; Agua-Doce A; Curotto de Lafaille MA; Lafaille JJ; Graca L Blood; 2013 May; 121(19):3936-45, S1. PubMed ID: 23532736 [TBL] [Abstract][Full Text] [Related]
10. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice. Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430 [TBL] [Abstract][Full Text] [Related]
11. Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A. Madoiwa S; Yamauchi T; Kobayashi E; Hakamata Y; Dokai M; Makino N; Kashiwakura Y; Ishiwata A; Ohmori T; Mimuro J; Sakata Y J Thromb Haemost; 2009 May; 7(5):811-24. PubMed ID: 19220731 [TBL] [Abstract][Full Text] [Related]
12. Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A. Madoiwa S; Yamauchi T; Hakamata Y; Kobayashi E; Arai M; Sugo T; Mimuro J; Sakata Y J Thromb Haemost; 2004 May; 2(5):754-62. PubMed ID: 15099282 [TBL] [Abstract][Full Text] [Related]
13. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy. Liu CL; Ye P; Yen BC; Miao CH Mol Ther; 2011 Aug; 19(8):1511-20. PubMed ID: 21468007 [TBL] [Abstract][Full Text] [Related]
14. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response. Waters B; Qadura M; Burnett E; Chegeni R; Labelle A; Thompson P; Hough C; Lillicrap D Blood; 2009 Jan; 113(1):193-203. PubMed ID: 18815284 [TBL] [Abstract][Full Text] [Related]
15. The humoral response to human factor VIII in hemophilia A mice. Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826 [TBL] [Abstract][Full Text] [Related]
16. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice. Kallas A; Kuuse S; Maimets T; Pooga M Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515 [TBL] [Abstract][Full Text] [Related]
17. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells. Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Chuah M; VandenDriessche T; Miao CH; Hough C; Lillicrap D Blood; 2009 Jul; 114(3):677-85. PubMed ID: 19458355 [TBL] [Abstract][Full Text] [Related]
18. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy. Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362 [TBL] [Abstract][Full Text] [Related]